RU2008142831A - Производные бензимидазола - Google Patents
Производные бензимидазола Download PDFInfo
- Publication number
- RU2008142831A RU2008142831A RU2008142831/04A RU2008142831A RU2008142831A RU 2008142831 A RU2008142831 A RU 2008142831A RU 2008142831/04 A RU2008142831/04 A RU 2008142831/04A RU 2008142831 A RU2008142831 A RU 2008142831A RU 2008142831 A RU2008142831 A RU 2008142831A
- Authority
- RU
- Russia
- Prior art keywords
- group
- alkyl
- formula
- halogen
- compound
- Prior art date
Links
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 title 1
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 26
- 229910052736 halogen Inorganic materials 0.000 claims abstract 15
- 150000002367 halogens Chemical class 0.000 claims abstract 13
- 125000001424 substituent group Chemical group 0.000 claims abstract 9
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims abstract 6
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims abstract 6
- 125000003277 amino group Chemical group 0.000 claims abstract 6
- 125000003118 aryl group Chemical group 0.000 claims abstract 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims abstract 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 6
- 125000002560 nitrile group Chemical group 0.000 claims abstract 6
- 150000003839 salts Chemical class 0.000 claims abstract 6
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims abstract 6
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims abstract 6
- 125000003396 thiol group Chemical group [H]S* 0.000 claims abstract 6
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims abstract 5
- 150000002148 esters Chemical class 0.000 claims abstract 5
- 239000000651 prodrug Substances 0.000 claims abstract 4
- 229940002612 prodrug Drugs 0.000 claims abstract 4
- 125000004399 C1-C4 alkenyl group Chemical group 0.000 claims abstract 3
- 125000006766 (C2-C6) alkynyloxy group Chemical group 0.000 claims abstract 2
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 claims abstract 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 4
- 108090000445 Parathyroid hormone Proteins 0.000 claims 4
- 210000000988 bone and bone Anatomy 0.000 claims 4
- 229910052791 calcium Inorganic materials 0.000 claims 4
- 239000011575 calcium Substances 0.000 claims 4
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 4
- 102100036893 Parathyroid hormone Human genes 0.000 claims 3
- 239000003153 chemical reaction reagent Substances 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000002140 halogenating effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000011164 ossification Effects 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 229940095743 selective estrogen receptor modulator Drugs 0.000 claims 2
- 239000000333 selective estrogen receptor modulator Substances 0.000 claims 2
- YZRCEDKJCYMCGB-UHFFFAOYSA-N 2-[3-[[7-methoxy-1-(2-methoxyethyl)-2-(4-propan-2-ylphenyl)-4-(trifluoromethyl)benzimidazol-5-yl]methyl]pyridin-2-yl]oxy-n,n-dimethylethanamine Chemical compound C=1C(OC)=C2N(CCOC)C(C=3C=CC(=CC=3)C(C)C)=NC2=C(C(F)(F)F)C=1CC1=CC=CN=C1OCCN(C)C YZRCEDKJCYMCGB-UHFFFAOYSA-N 0.000 claims 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- HNXCBYBLDPXLMN-UHFFFAOYSA-N 4-bromo-7-methoxy-1-(2-methoxyethyl)-5-[(2-methylsulfanylpyridin-3-yl)methyl]-2-(4-propan-2-ylphenyl)benzimidazole Chemical compound C=1C(OC)=C2N(CCOC)C(C=3C=CC(=CC=3)C(C)C)=NC2=C(Br)C=1CC1=CC=CN=C1SC HNXCBYBLDPXLMN-UHFFFAOYSA-N 0.000 claims 1
- ZJKMBBWISFOMSY-UHFFFAOYSA-N 4-bromo-7-methoxy-1-(2-methoxyethyl)-5-[(2-methylsulfinylpyridin-3-yl)methyl]-2-(4-propan-2-ylphenyl)benzimidazole Chemical compound C=1C(OC)=C2N(CCOC)C(C=3C=CC(=CC=3)C(C)C)=NC2=C(Br)C=1CC1=CC=CN=C1S(C)=O ZJKMBBWISFOMSY-UHFFFAOYSA-N 0.000 claims 1
- 125000004861 4-isopropyl phenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- MXMSONJMVWOEPO-UHFFFAOYSA-N 5-[(2-ethoxypyridin-3-yl)methyl]-7-methoxy-1-(2-methoxyethyl)-2-(4-propan-2-ylphenyl)-4-(trifluoromethyl)benzimidazole Chemical compound CCOC1=NC=CC=C1CC1=CC(OC)=C(N(CCOC)C(=N2)C=3C=CC(=CC=3)C(C)C)C2=C1C(F)(F)F MXMSONJMVWOEPO-UHFFFAOYSA-N 0.000 claims 1
- NIQSGWJDOXIURI-UHFFFAOYSA-N 7-methoxy-1-(2-methoxyethyl)-5-[(2-methoxypyridin-3-yl)methyl]-2-(4-propan-2-ylphenyl)-4-(trifluoromethyl)benzimidazole Chemical compound C=1C(OC)=C2N(CCOC)C(C=3C=CC(=CC=3)C(C)C)=NC2=C(C(F)(F)F)C=1CC1=CC=CN=C1OC NIQSGWJDOXIURI-UHFFFAOYSA-N 0.000 claims 1
- XJIQNOQRLZSHST-UHFFFAOYSA-N 7-methoxy-1-(2-methoxyethyl)-5-[(2-methylsulfanylpyridin-3-yl)methyl]-2-(4-propan-2-ylphenyl)-4-(trifluoromethyl)benzimidazole Chemical compound C=1C(OC)=C2N(CCOC)C(C=3C=CC(=CC=3)C(C)C)=NC2=C(C(F)(F)F)C=1CC1=CC=CN=C1SC XJIQNOQRLZSHST-UHFFFAOYSA-N 0.000 claims 1
- STKOFLRHQQCLDD-UHFFFAOYSA-N 7-methoxy-1-(2-methoxyethyl)-5-[(2-methylsulfinylpyridin-3-yl)methyl]-2-(4-propan-2-ylphenyl)-4-(trifluoromethyl)benzimidazole Chemical compound C=1C(OC)=C2N(CCOC)C(C=3C=CC(=CC=3)C(C)C)=NC2=C(C(F)(F)F)C=1CC1=CC=CN=C1S(C)=O STKOFLRHQQCLDD-UHFFFAOYSA-N 0.000 claims 1
- XNEWILNREVDHDJ-UHFFFAOYSA-N 7-methoxy-1-(2-methoxyethyl)-5-[(2-methylsulfonylpyridin-3-yl)methyl]-2-(4-propan-2-ylphenyl)-4-(trifluoromethyl)benzimidazole Chemical compound C=1C(OC)=C2N(CCOC)C(C=3C=CC(=CC=3)C(C)C)=NC2=C(C(F)(F)F)C=1CC1=CC=CN=C1S(C)(=O)=O XNEWILNREVDHDJ-UHFFFAOYSA-N 0.000 claims 1
- MFUFZKHPBQXMBL-UHFFFAOYSA-N 7-methoxy-1-(2-methoxyethyl)-5-[(2-propan-2-yloxypyridin-3-yl)methyl]-2-(4-propan-2-ylphenyl)-4-(trifluoromethyl)benzimidazole Chemical compound C=1C(OC)=C2N(CCOC)C(C=3C=CC(=CC=3)C(C)C)=NC2=C(C(F)(F)F)C=1CC1=CC=CN=C1OC(C)C MFUFZKHPBQXMBL-UHFFFAOYSA-N 0.000 claims 1
- GXMQKRXNPGPMHC-UHFFFAOYSA-N 7-methoxy-5-[[2-(2-methoxyethoxy)pyridin-3-yl]methyl]-1-(2-methoxyethyl)-2-(4-propan-2-ylphenyl)-4-(trifluoromethyl)benzimidazole Chemical compound COCCOC1=NC=CC=C1CC1=CC(OC)=C(N(CCOC)C(=N2)C=3C=CC(=CC=3)C(C)C)C2=C1C(F)(F)F GXMQKRXNPGPMHC-UHFFFAOYSA-N 0.000 claims 1
- 229940122361 Bisphosphonate Drugs 0.000 claims 1
- 102000055006 Calcitonin Human genes 0.000 claims 1
- 108060001064 Calcitonin Proteins 0.000 claims 1
- 229940122156 Cathepsin K inhibitor Drugs 0.000 claims 1
- 102000003982 Parathyroid hormone Human genes 0.000 claims 1
- 229930003316 Vitamin D Natural products 0.000 claims 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 150000004663 bisphosphonates Chemical class 0.000 claims 1
- 229960004015 calcitonin Drugs 0.000 claims 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000012434 nucleophilic reagent Substances 0.000 claims 1
- 125000002524 organometallic group Chemical group 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 239000000199 parathyroid hormone Substances 0.000 claims 1
- 229960001319 parathyroid hormone Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000003270 steroid hormone Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 235000019166 vitamin D Nutrition 0.000 claims 1
- 239000011710 vitamin D Substances 0.000 claims 1
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 1
- 229940046008 vitamin d Drugs 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 0 CC(C)c(cc1)ccc1-c1nc2c(*)c(*c(cccn3)c3S*)cc(OC)c2[n]1CCOC Chemical compound CC(C)c(cc1)ccc1-c1nc2c(*)c(*c(cccn3)c3S*)cc(OC)c2[n]1CCOC 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0606426.5A GB0606426D0 (en) | 2006-03-30 | 2006-03-30 | Benzimidazole derivatives |
| GB0606426.5 | 2006-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008142831A true RU2008142831A (ru) | 2010-05-10 |
Family
ID=36424926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008142831/04A RU2008142831A (ru) | 2006-03-30 | 2007-03-28 | Производные бензимидазола |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20100227889A1 (enExample) |
| EP (1) | EP2004629A2 (enExample) |
| JP (1) | JP2009531363A (enExample) |
| KR (1) | KR20080110769A (enExample) |
| CN (1) | CN101400669A (enExample) |
| AR (1) | AR060334A1 (enExample) |
| AU (1) | AU2007234021B2 (enExample) |
| BR (1) | BRPI0710180A2 (enExample) |
| CA (1) | CA2644380A1 (enExample) |
| CL (1) | CL2007000850A1 (enExample) |
| CR (1) | CR10199A (enExample) |
| EC (1) | ECSP088781A (enExample) |
| GB (1) | GB0606426D0 (enExample) |
| GT (1) | GT200800200A (enExample) |
| IL (1) | IL193475A0 (enExample) |
| MA (1) | MA30341B1 (enExample) |
| MX (1) | MX2008012403A (enExample) |
| NO (1) | NO20084543L (enExample) |
| PE (1) | PE20071149A1 (enExample) |
| RU (1) | RU2008142831A (enExample) |
| TN (1) | TNSN08369A1 (enExample) |
| TW (1) | TW200806647A (enExample) |
| WO (1) | WO2007112913A2 (enExample) |
| ZA (1) | ZA200806833B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1993559T1 (sl) | 2006-02-03 | 2017-01-31 | Opko Renal, Llc | Zdravljenje nezadostnosti in pomanjkanja vitamina D s 25-hidroksivitaminon D2 in 25-hidroksivitaminom D3 |
| PT2679228T (pt) | 2006-06-21 | 2018-04-16 | Opko Ireland Global Holdings Ltd | Terapia utilizando um agente de repleção de vitamina d e um agente de substituição hormonal de vitamina d |
| CN104257667B (zh) | 2007-04-25 | 2019-06-04 | 欧普科Ip 控股Ii 有限公司 | 治疗维生素d不足和缺乏、继发性甲状旁腺功能亢进症和维生素d-响应疾病的方法和组合物 |
| KR101959952B1 (ko) | 2007-04-25 | 2019-03-19 | 사이토크로마 인코포레이티드 | 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물 |
| ES2783980T3 (es) | 2010-03-29 | 2020-09-21 | Opko Ireland Global Holdings Ltd | Métodos y composiciones para la reducción de niveles de paratiroides |
| EP2643298A1 (en) * | 2010-11-26 | 2013-10-02 | Leo Pharma A/S | Substituted cyclopentyl - azines as casr- active compounds |
| KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 ｄ 방출 제형 |
| US10220047B2 (en) | 2014-08-07 | 2019-03-05 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| MY198547A (en) | 2016-03-28 | 2023-09-04 | Opko Ireland Global Holdings Ltd | Methods of vitamin d treatment |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000026430A (ja) * | 1998-07-02 | 2000-01-25 | Taisho Pharmaceut Co Ltd | ２、５、６−置換ベンズイミダゾール化合物誘導体 |
| US6362202B1 (en) * | 1999-03-02 | 2002-03-26 | Sepracor Inc. | Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists |
| WO2004041277A1 (en) * | 2002-11-01 | 2004-05-21 | Merck & Co., Inc. | Carbonylamino-benzimidazole derivatives as androgen receptor modulators |
| GB0400781D0 (en) * | 2004-01-14 | 2004-02-18 | Novartis Ag | Organic compounds |
| EP1964548A1 (en) * | 2007-03-02 | 2008-09-03 | Novartis AG | Pharmaceutical compositions comprising a calcilytic agent |
-
2006
- 2006-03-30 GB GBGB0606426.5A patent/GB0606426D0/en not_active Ceased
-
2007
- 2007-03-28 KR KR1020087023787A patent/KR20080110769A/ko not_active Withdrawn
- 2007-03-28 AR ARP070101297A patent/AR060334A1/es not_active Application Discontinuation
- 2007-03-28 JP JP2009501943A patent/JP2009531363A/ja not_active Withdrawn
- 2007-03-28 BR BRPI0710180-5A patent/BRPI0710180A2/pt not_active IP Right Cessation
- 2007-03-28 EP EP07723708A patent/EP2004629A2/en not_active Withdrawn
- 2007-03-28 WO PCT/EP2007/002763 patent/WO2007112913A2/en not_active Ceased
- 2007-03-28 PE PE2007000352A patent/PE20071149A1/es not_active Application Discontinuation
- 2007-03-28 RU RU2008142831/04A patent/RU2008142831A/ru not_active Application Discontinuation
- 2007-03-28 CN CNA2007800087520A patent/CN101400669A/zh active Pending
- 2007-03-28 MX MX2008012403A patent/MX2008012403A/es not_active Application Discontinuation
- 2007-03-28 AU AU2007234021A patent/AU2007234021B2/en not_active Ceased
- 2007-03-28 CA CA002644380A patent/CA2644380A1/en not_active Abandoned
- 2007-03-28 US US12/295,381 patent/US20100227889A1/en not_active Abandoned
- 2007-03-29 CL CL200700850A patent/CL2007000850A1/es unknown
- 2007-03-29 TW TW096111055A patent/TW200806647A/zh unknown
-
2008
- 2008-08-07 ZA ZA200806833A patent/ZA200806833B/xx unknown
- 2008-08-11 CR CR10199A patent/CR10199A/es not_active Application Discontinuation
- 2008-08-14 IL IL193475A patent/IL193475A0/en unknown
- 2008-09-22 TN TNP2008000369A patent/TNSN08369A1/en unknown
- 2008-09-29 GT GT200800200A patent/GT200800200A/es unknown
- 2008-09-30 EC EC2008008781A patent/ECSP088781A/es unknown
- 2008-10-17 MA MA31302A patent/MA30341B1/fr unknown
- 2008-10-28 NO NO20084543A patent/NO20084543L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007234021A1 (en) | 2007-10-11 |
| WO2007112913A3 (en) | 2007-12-21 |
| TNSN08369A1 (en) | 2009-12-29 |
| WO2007112913A2 (en) | 2007-10-11 |
| CA2644380A1 (en) | 2007-10-11 |
| US20100227889A1 (en) | 2010-09-09 |
| IL193475A0 (en) | 2009-05-04 |
| JP2009531363A (ja) | 2009-09-03 |
| AU2007234021B2 (en) | 2011-04-28 |
| TW200806647A (en) | 2008-02-01 |
| GT200800200A (es) | 2008-11-10 |
| BRPI0710180A2 (pt) | 2011-08-09 |
| CN101400669A (zh) | 2009-04-01 |
| PE20071149A1 (es) | 2007-12-04 |
| CR10199A (es) | 2008-10-16 |
| GB0606426D0 (en) | 2006-05-10 |
| MA30341B1 (fr) | 2009-04-01 |
| KR20080110769A (ko) | 2008-12-19 |
| AR060334A1 (es) | 2008-06-11 |
| CL2007000850A1 (es) | 2008-03-14 |
| NO20084543L (no) | 2008-10-21 |
| MX2008012403A (es) | 2008-10-07 |
| ECSP088781A (es) | 2008-10-31 |
| ZA200806833B (en) | 2009-05-27 |
| EP2004629A2 (en) | 2008-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008142831A (ru) | Производные бензимидазола | |
| JP6434482B2 (ja) | 置換アシルアニリドおよびそれらの使用方法 | |
| PH12023550130A1 (en) | Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of using same | |
| JP5745560B2 (ja) | 置換アシルアニリドおよびそれらの使用方法 | |
| JP2009531363A5 (enExample) | ||
| JP5123671B2 (ja) | 増殖性疾患の治療のための化合物 | |
| RU2008109654A (ru) | Производные бензохиназолина и их применение для лечения костных нарушений | |
| JP6907351B2 (ja) | 選択的アンドロゲン受容体モジュレーターとしてのカルボニトリル誘導体 | |
| RU2008127750A (ru) | Антивирусные нуклеозиды | |
| JP2009504763A5 (enExample) | ||
| RU2008106058A (ru) | Производные пиридазинона в качестве агонистов рецептора тиреоидного гормона | |
| RU2009102278A (ru) | Модуляторы рецептора s1p для лечения рассеянного склероза | |
| RU2004104625A (ru) | Аналоги простагландинов в качестве агонистов рецептора ep4 | |
| JP2005536475A5 (enExample) | ||
| NO20071058L (no) | Risedronatsammensetninger og deres fremgangsmater for anvendelse | |
| EP2682387A3 (en) | C7-fluoro substituted tetracycline compounds | |
| JP2020507589A5 (enExample) | ||
| BR0314126A (pt) | Ligandos de amida acìclica e sulfonamida para o receptor de estrogênio | |
| JP2010503674A (ja) | 血管形成治療用化合物 | |
| JP2008546717A5 (enExample) | ||
| JP6039100B2 (ja) | 新規選択的アンドロゲン受容体モジュレーター | |
| JP2014528464A5 (enExample) | ||
| TWI694986B (zh) | 經取代之吡啶基-環烷基-羧酸、包含其之組合物及其用途 | |
| JP2019524797A5 (enExample) | ||
| EA200801261A1 (ru) | Фармацевтические композиции на основе галлия и способы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20110610 |